Regeneron Pharmaceuticals recently reported its fourth-quarter earnings, which, though lower than last year's figures, surpassed market expectations. The company’s net income was $1.16 billion, equivalent to $10.19 per share. The prior year's fourth quarter saw the bottom line at $1.20 billion, translating to $10.50 per share.
Accounting for certain factors, Regeneron's adjusted earnings for the quarter amounted to $1.37 billion, or $11.86 per share. The average analyst forecast was at $10.77 per share, according to data compiled by Thomson Reuters. It's worth mentioning that analyst projections generally do not consider exceptional items.
Moreover, the company's quarterly revenue experienced a slight increase, growing by 0.6% to $3.43 billion from $3.41 billion the previous year.
To sum it up for Regeneron Pharmaceuticals, the GAAP figures suggest:
- Fourth quarter earnings: $1.16 Bln, a drop from last year's $1.20 Bln.
- Earnings per share during the fourth quarter: $10.19, slightly lower than $10.50 the previous year.
- Market predictions were pegged at $10.77.
- Fourth quarter revenue: $3.43 Bln, an improvement from $3.41 Bln last year.
